- Home
- Companies
- Claret Bioscience
- Applications
Claret Bioscience applications
This application note describes the utility of SRSLY in performing targeted sequence analysis of SAR-CoV-2 RNA-Seq libraries were generated with SRSLY within 3 hours. Subsequent enrichment of viral sequences can be performed with a user-preferred hybridization-based panel.
SRSLY NGS library preparation with twist exome panel enrichment for ctDNA SNP profiling. Cell-free DNA (cfDNA), found circulating in blood, originates predominantly from dying cells. In healthy individuals the vast majority of cfDNA derives from hematopoietic myeloid and lymph cells undergoing apoptosis. However, in individuals with cancer, a variable fraction of the cfDNA derives from tumor cells undergoing apoptosis and/or necrosis. This tumor derived fraction of cfDNA is known as circulating tumor DNA (ctDNA). The amount of ctDNA found in an individual with cancer depends on numerous parameters such as tumor growth rate, metastasis, and overall tumor size
Cell-free DNA (cfDNA), found circulating in blood plasma, contains a wealth of clinically relevant biological information which can be recovered by minimally-invasive procedures. Next Generation Sequencing (NGS) data obtained from cfDNA, can be used to monitor prenatal health, organ transplant reception or rejection, cancer and other diseases.